Table 6.
Diagnostic monitoring of immunoglobulins by CLIA test serological protocol from published data
| Citation | Product name/source | Antibody assessment type | Detection time range (d) | Mean time of detection (d) | Peak period (d) | !Period of decline (d) |
|---|---|---|---|---|---|---|
| Long et al.72 | MCLIA kits (Bioscience Co.; approved by the China National Medical Products Administration) | Total | 2–4 | 2 | 11–13 | >23 |
| IgG | 2–4 | 4 | 11–13 | >23 | ||
| IgM | 2–4 | 2 | 11–13 | >23 | ||
| Jin et al.23 | CLIA test kit Shenzhen YHLO Biotech Co., Ltd (China) | Total | 1–5 | 1 | 16–20 | >32 |
| IgG | 1–5 | 5 | 16–20 | >32 | ||
| IgM | 1–5 | 1 | 16–20 | 21–25 | ||
| Padoan et al.70 | CLIA assay (MAGLUMI 2000 Plus) | Total | NAb | NAb | NAb | NAb |
| IgG | NAb | NAb | NAb | NAb | ||
| IgM | 4 | 4 | 12 | 34 | ||
| Padoan et al.73 | MAGLUMI 2000 Plus 2019-nCov IgM and IgG assays (Snibe, Shenzhen, China) | Total | <5 | <5 | 26–30 | >30 |
| IgG | <5 | <5 | 26–30 | >30 | ||
| IgM | <5 | <5 | 12–13 | 18–19 | ||
| Wolff et al.63 | Elecsys anti-SARS CoV-2 IgM/IgG assay (Roche Diagnostics, Vilvoorde, Belgium) | Total | 4 | 4 | 11 | >24 |
| IgG | NAb | NAb | NAb | NAb | ||
| IgM | NAb | NAb | NAb | NAb | ||
| Liaison SARS-CoV-2 IgG kit (CLIA) (Diasorin, Saluggia, Italy) | Total | NAb | NAb | NAb | NAb | |
| IgG | 4 | 4 | 11–13 | >24 | ||
| IgM | NAb | NAb | NAb | NAb | ||
| Hou et al.74 | Anti-SARS-CoV-2 CLIA-YHLO kit | Total | ||||
| IgG | 3 | 3 | 48 | >48 | ||
| IgM | 3 | 3 | 30 | 48 | ||
| Montesinos et al.55 | Maglumi 2019-n-Cov IgG and IgM (CLIA) | Total | 0–7 | 4 | >15 | >15 |
| IgG | 0–7 | 7 | >15 | >15 | ||
| IgM | 0–7 | 4 | >15 | >15 | ||
| Ma et al.67 | CLIA RBD-specific anti-SARS-CoV-2 IgA, IgM, and IgG kit | Total | NAb | NAb | NAb | NAb |
| IgG | 4–10 | 10 | 16–41 | >41 | ||
| IgM | 4–10 | 7 | 11–30 | 31–41 | ||
| IgA | 4–10 | 7 | 11–20 | 21–25 | ||
| Qian et al.68 | CLIA test kit Shenzhen YHLO Biotech Co., Ltd (China) | Total | NAb | NAb | NAb | NAb |
| IgG | 6 | 6 | 20 | >35 | ||
| IgM | 6 | 6 | 20 | 35 | ||
| Suhandynata et al.69 | Diazyme DZ-LITE 2019-nCoV IgG (CLIA) assay kit (cat. # 130219015M)/IgM (CLIA) assay kit (cat. # 130219016M) | Total | NAb | NAb | NAb | NAb |
| IgG | 2–6 | 6 | 8–22 | ≥24 | ||
| IgM | 0–4 | 3 | 6–8 | 14–22 |
Abbreviations: CLIA, chemiluminescence immunoassay; NAb, not available; POS, postonset of symptoms; RBD, receptor-binding domain.
Note:
1. All computed values were POS.